Senegal sequences its first 40 human whole genomes

A laboratory in Dakar has done something that has never been done before in Senegal: sequenced a complete human genome. In a programme announced by Institut Pasteur de Dakar, researchers completed 40 whole human genome sequences, using Illumina and Oxford Nanopore Technologies platforms — two of the most widely used tools in modern genomic research.

The sequencing work sits inside a larger clinical and bioinformatics platform the institute has launched. According to Institut Pasteur de Dakar, the platform is now able to test for genetic predisposition to early-onset breast cancer and other rare heritable gene changes — conditions that have historically gone undetected in Senegal for want of local infrastructure.

The programme brings together genomics, infectious disease research, and environmental data, the institute said, describing it as a multidisciplinary effort to address the growing burden of cancer across Senegal and the wider African continent.

Why this reaches the albinism community

For people with albinism across West Africa, the arrival of a functioning genomic platform on the continent carries quiet, specific significance. Albinism is caused by variants in genes including OCA1, OCA2, and TYRP1 — the last of which is found at elevated frequency in sub-Saharan African populations, according to published genetic literature. Until now, confirming a diagnosis, identifying a specific gene variant, or assessing cancer risk required sending samples abroad, often at prohibitive cost and with long delays.

A local platform capable of sequencing heritable gene changes could, in time, make carrier testing and early intervention more accessible to families across the region. The institute has not yet specified whether albinism-related gene variants are within the current scope of testing, but the infrastructure now exists in-country for that conversation to begin.

Skin cancer remains the most serious and most preventable health risk facing people with albinism in sun-intense climates. Early detection depends on access — access to dermatological care, to SPF-rated sunscreen, and increasingly, to genetic information that can clarify individual risk profiles. A genomic platform in Dakar does not solve sunscreen scarcity or clinic access. But it places one more tool closer to the people who need it.

The full scope of the research programme, including which cancers and heritable conditions will be prioritised, has not yet been published in detail by the institute.